Evaluated by: Laura W. Lamps, M.D., UAMS Health, M.D., FIAC, July 8, 2016
Original release date: July 7, 2016
Access to this course expires on: July 7, 2019
This course provides registrants an overview of inherited gynecologic cancer syndromes with emphasis on BRCA-associated and Lynch syndromes. Specific topics include: biological and clinical underpinnings of BRCA1 and BRCA2 dysfunction and PARP function; current models of serous carcinogenesis; how to assess for hereditary ovarian cancer risk- importance of genetic counseling and the use of pathology and family history as risk assessment tools; ovarian cancer risk reduction strategies, including chemoprevention, surveillance and risk reducing surgery; proper grossing techniques for risk reducing (i.e. prophylactic) salpingo-oophorectomy specimens; criteria for the diagnosis of intraepithelial serous carcinoma of the fallopian tube and the distinction of this lesion from mimics; strategies for diagnosing both grossly visibly and clinically inapparent lesions in salpingo-oophorectomy specimens; current concepts of the morphologic phenotype of BRCA1 associated ovarian, tubal and peritoneal carcinoma; biological and clinical attributes of BRCA1 inactivated ovarian, tubal and peritoneal carcinoma, including an introduction to the rationale for targeted therapy; biological and clinical underpinnings of Lynch syndrome in endometrial and ovarian cancer; rationale behind assessment for hereditary cancer risk in patients with endometrial cancer; risk assessment for Lynch Syndrome genetic counseling, family history and pathology; techniques used to determine Lynch syndrome risk in patients with endometrial cancer, including morphologic, immunohistochemical and molecular diagnostic examination; algorithms used to determine Lynch syndrome risk; ethical and regulatory issues concerning screening patients for cancer predisposition syndromes. The genetic basis, clinical presentation and morphologic features of tumors associated with other, less common gynecologic cancer syndromes will also be covered: Peutz Jeghers; Cowden; Hereditary leiomyomatosis/renal cell carcinoma; Tuberous sclerosis; Ataxia telangiectasia.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
To earn CME and SAM credit, all learners must take a content-based exam and achieve a minimum score of 80%. If learners do not achieve a passing score of 80%, they have the option to retake the exam. After you pass the test and complete the evaluation, your certificate of completion will be available to view and print by clicking here.
Not A Member? Click Here